Singapore Paincare (SGX:FRQ) disclosed a qualified opinion from auditors BDO LLP for its financial statements for the year ended June 30, 2024, according to a Thursday filing on the Singapore Exchange.
The group's goodwill, valued at $13.5 million, was assessed for impairment using a value-in-use method, with no impairment loss recognized. The assessment of investments in subsidiaries, totaling around $5 million, also showed no impairment loss.
Additionally, the fair value of financial assets held by the group's joint venture, Singapore Paincare Capital, was recorded at about $8.8 million, contributing to a fair value gain of $578,000.